Summaries & Highlights
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la/mUC), NIAGARA (MIBC), and AMBASSADOR (MIUC)
FEATURING
Elizabeth R. Plimack
- 8 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Updates in the Treatment of MCL
FEATURING
Georg Hess
- 23 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: ctDNA and Molecular Screening for Target Detection and Treatment Monitoring in mBC
FEATURING
Michail Ignatiadis
- 7 views
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, DESTINY-BREAST12, and CAPItello-290
FEATURING
Virginia Kaklamani
- 138 views
- September 23, 2024
- 6
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Selecting 1L Therapy and Sequencing After Immunotherapy in Unresectable HCC
FEATURING
Lorenza Rimassa
- 140 views
- September 20, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Key Trial Results in Advanced Bladder Cancer Treatment
FEATURING
Guru Sonpavde
- 41 views
- September 24, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Head & Neck Cancer Highlights
FEATURING
Nabil Saba
- 60 views
- September 23, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Practice-Changing Trials for Patients With Localized MIBC - NIAGARA and AMBASSADOR
FEATURING
Petros Grivas
- 141 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in Heme Malignancies
FEATURING
Maria Gomes da Silva
- 141 views
- September 23, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: dMMR Advanced/Recurrent Endometrial Cancer - Advances, Wins, and Challenges
FEATURING
Mansoor Raza Mirza
- 97 views
- September 20, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Late-Line Therapy in mCRC - How to Choose
FEATURING
Howard Hochster
- 97 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-Breast12, KEYNOTE-522, CAPItello-290 & ICARUS-Breast01
FEATURING
Paolo Tarantino
- 147 views
- September 24, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Advances in Cervical Cancer Management - Comprehensive Strategies for Recurrent or Metastatic Disease
FEATURING
Domenica Lorusso
- 36 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials
FEATURING
Douglas Johnson
- 18 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Metastatic Melanoma Highlights
FEATURING
Christian Blank
- 43 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: The Latest Data on NMIBC and Localized MIBC
FEATURING
Félix Guerrero-Ramos
- 24 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mCRPC) and NIAGARA (MIBC)
FEATURING
Robert Dreicer
- 45 views
- September 24, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Bladder Cancer Highlights - JCOG1019, TOMBOLA, and SunRISe-4
FEATURING
Bogdana Schmidt
- 12 views
- September 23, 2024
Breast
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Real-World Characteristics of NATALEE and monarchE Eligible Populations - A US Electronic Health Records Analysis
FEATURING
Paolo Tarantino
- 4 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: ctDNA and Molecular Screening for Target Detection and Treatment Monitoring in mBC
FEATURING
Michail Ignatiadis
- 7 views
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Breast Cancer Highlights - KEYNOTE-522, NATALEE, DESTINY-BREAST12, and CAPItello-290
FEATURING
Virginia Kaklamani
- 138 views
- September 23, 2024
- 6
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Top 5 Breast Cancer Abstracts - NATALEE, DESTINY-Breast12, KEYNOTE-522, CAPItello-290 & ICARUS-Breast01
FEATURING
Paolo Tarantino
- 147 views
- September 24, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: CAPItello-290 Trial - Capivasertib + Paclitaxel as 1L Treatment for mTNBC
FEATURING
Heather McArthur
- 67 views
- September 24, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Pembro or Placebo + CT in High-Risk Early TNBC - OS Results From KEYNOTE-522
FEATURING
Heather McArthur
- 60 views
- September 24, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: DETECT V trial - Omission of Chemo and Addition of the CDK4/6i Ribociclib in HER2+ and HR+ mBC
FEATURING
Wolfgang Janni
- 7 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: PROMENADE Trial - Pembro for Early ER-Low/HER2- BC - Real World French Cohort
FEATURING
Francois Cherifi
- 52 views
- September 23, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: DESTINY-Breast06 Trial - HER2-Low and HER2-Ultralow Status Determination in Tumors of Patients With HR+ mBC
FEATURING
Giuseppe Viale
- 10 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Hypo vs. Normofractionated RT in eBC - 5-Year Results of HypoG-01
FEATURING
Sofia Rivera
- 67 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Prognostic Role of TILs on OS and Treatment De-Escalation in HER2+ Early BC in the ShortHER Trial
FEATURING
Maria Vittoria Dieci
- 75 views
- September 19, 2024
GI
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: POD1UM-303/InterAACT 2 - Retifanlimab + C-P in Untreated Inoperable or Metastatic Anal Squamous Cell Carcinoma
FEATURING
Sheela Rao
- 5 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Nal-IRI/LV5-FU vs. Paclitaxel as 2L Therapy in Metastatic Esophageal SCC - OESIRI-PRODIGE 62 Study
FEATURING
David Tougeron
- 3 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Pembro + CAPOX + Bevacizumab in MSS mCRC With High Immune Infiltrate - FFCD 1703 POCHI Trial
FEATURING
David Tougeron
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Treatment Strategies and Sequencing in Carcinoid Syndrome
FEATURING
Rachel Riechelmann
- 47 views
- September 24, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Late-Line Therapy in mCRC - How to Choose
FEATURING
Howard Hochster
- 97 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Selecting 1L Therapy and Sequencing After Immunotherapy in Unresectable HCC
FEATURING
Lorenza Rimassa
- 140 views
- September 20, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: TACE ± Lenvatinib + Pembro for Int-Stage HCC - Ph3 LEAP-012 Study
FEATURING
Josep Llovet
- 59 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: HIMALAYA - 5-Year OS of Tremelimumab + Durvalumab in Unresectable HCC
FEATURING
Lorenza Rimassa
- 93 views
- September 20, 2024
GU
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: EMBARK Study Post-Hoc Analysis By Age - Enzalutamide +/- Leuprolide in Patients With High-Risk Biochemically Recurrent Prostate Cancer
FEATURING
Neal Shore
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la/mUC), NIAGARA (MIBC), and AMBASSADOR (MIUC)
FEATURING
Elizabeth R. Plimack
- 8 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Key Trial Results in Advanced Bladder Cancer Treatment
FEATURING
Guru Sonpavde
- 41 views
- September 24, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mCRPC) and NIAGARA (MIBC)
FEATURING
Robert Dreicer
- 45 views
- September 24, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: The Latest Data on NMIBC and Localized MIBC
FEATURING
Félix Guerrero-Ramos
- 24 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Bladder Cancer Highlights - JCOG1019, TOMBOLA, and SunRISe-4
FEATURING
Bogdana Schmidt
- 12 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Practice-Changing Trials for Patients With Localized MIBC - NIAGARA and AMBASSADOR
FEATURING
Petros Grivas
- 141 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Final Analysis of the Phase 3 LITESPARK-005 Study of Belzutifan vs. Everolimus in Patients With Previously Treated Advanced ccRCC
FEATURING
Brian Rini
- 18 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: RAPSON Study - Radium223-Docetaxel vs. Docetaxel-Radium223 Sequence in mCRPC with Prospective Biomarker Evaluation
FEATURING
Vincenza Conteduca
- 1 view
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: STAMPEDE2 Comparison P - Upfront Accelerated 177Lu-PSMA-617 in mHSPC
FEATURING
Minal Padden-Modi,
Nick James
- 3 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: TACITO Trial - Fecal Microbiota Transplantation vs. Placebo in Patients Receiving Pembro + Axitinib for mRCC
FEATURING
Chiara Ciccarese
- 15 views
- September 24, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: STAMPEDE2 Trial - Stereotactic Ablative Body Radiotherapy for Newly Diagnosed Oligometastatic Prostate Cancer Starting ADT
FEATURING
Hoda Abdel-Aty
- 11 views
- September 24, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: PEACE-1 Trial - Phenotypic and Genomic Characterization of De Novo Metastatic Prostate Cancer
FEATURING
Cedric Pobel
- 3 views
- September 24, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: VOLGA Trial - ctDNA Clearance in Cisplatin-Ineligible MIBC With Durvalumab + Tremelimumab + Enfortumab Vedotin
FEATURING
Alexandra Drakaki
- 21 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: SOGUG-AUREA Study - Split-Dose Cisplatin and Atezolizumab in Cisplatin-Ineligible Urothelial Carcinoma
FEATURING
Guillermo de Velasco
- 24 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Predictive Tumor Suppressor Gene Signature for Early Progression in mHSPC
FEATURING
Marta Garcia De Herreros
- 6 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: SC vs. IV Nivolumab in Advanced/Metastatic RCC - Ph3 CheckMate 67T
FEATURING
Laurence Albiges
- 70 views
- September 19, 2024
GYN
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Induction Chemo Followed by CRT in Advanced Cervical Cancer - QoL Outcomes From GCIG INTERLACE
FEATURING
Gemma Eminowicz
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Pembro or Placebo in Combination With Adjuvant Chemo +/- RT in Pts With Newly Diagnosed, High-Risk Endometrial Cancer From ENGOT-EN11/GOG-3053/KEYNOTE-B21
FEATURING
Brian Slomovitz
- 9 views
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Final OS from the ATALANTE/ENGOT-ov29 Trial Evaluating Atz vs. Placebo with Standard Cx + Bev in Ovarian Cancer Patients with Platinum-Sensitive Relapse
FEATURING
Jean-Emmanuel Kurtz
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Clinical and Molecular Predictors of Outcome in Patients With Tubo-Ovarian High-Grade Serous Carcinoma and Exceptional Survival
FEATURING
Tibor A. Zwimpfer
- 11 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Advances in Cervical Cancer Management - Comprehensive Strategies for Recurrent or Metastatic Disease
FEATURING
Domenica Lorusso
- 36 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: dMMR Advanced/Recurrent Endometrial Cancer - Advances, Wins, and Challenges
FEATURING
Mansoor Raza Mirza
- 97 views
- September 20, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: OS Results for Pembro + CRT for High-Risk Locally Advanced Cervical Cancer - ENGOT-cx11/GOG-3047/KEYNOTE-A18
FEATURING
Domenica Lorusso
- 63 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Rucaparib +/- Nivo as Maintenance in Newly Diagnosed Ovarian Cancer - ATHENA-COMBO Ph3 Trial
FEATURING
Bradley J. Monk
- 152 views
- September 19, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Final OS With Niraparib as 1L Maintenance in Advanced Ovarian Cancer - PRIMA Trial
FEATURING
Bradley J. Monk
- 153 views
- September 19, 2024
- 1
Head & Neck
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Head & Neck Cancer Highlights
FEATURING
Nabil Saba
- 60 views
- September 23, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Neoadjuvant Chemo Followed by Surgery & Post-Operative RT vs. Surgery & Post-Operative RT for Organ Preservation of T3 & T4a Nasal and Paranasal Sinus SCC
FEATURING
Nabil Saba
- 25 views
- September 23, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: GORTEC 2017-01 REACH Trial - Avelumab-Cetuximab-RT vs. Standards of Care in Patients With Locally Advanced SCC of Head & Neck
FEATURING
Yungan Tao
- 8 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Avelumab-Cetuximab-RT vs. SoC in Locally Advanced HNSCC - Final Analysis From the REACH Trial
FEATURING
Makoto Tahara
- 51 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Setanaxib + Pembro in Recurrent or Metastatic HNSCC
FEATURING
Makoto Tahara
- 25 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: 3-Weekly vs. Weekly Cisplatin in High-Risk HNSCC Post-Op CRT - Final Results of JCOG1008
FEATURING
Makoto Tahara
- 30 views
- September 20, 2024
Skin
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Key Metastatic and Neoadjuvant Melanoma Trials
FEATURING
Douglas Johnson
- 18 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Metastatic Melanoma Highlights
FEATURING
Christian Blank
- 43 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: CFT1946, a Novel BRAF V600X Degrader, in Preliminary Results in BRAF V600 Mutant Solid Tumors
FEATURING
Maria Vieito
- 7 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Nivo + Ipi ± ASTX727 in Anti-PD-1 Resistant Metastatic Melanoma - NIBIT-ML1 Ph2 Study
FEATURING
Anna Maria Di Giacomo
- 41 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Survival Impact of Adjuvant Treatment in Stage III Melanoma
FEATURING
Hildur Helgadottir
- 43 views
- September 20, 2024
Hematologic Oncology
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Updates in the Treatment of MCL
FEATURING
Georg Hess
- 23 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in Heme Malignancies
FEATURING
Maria Gomes da Silva
- 141 views
- September 23, 2024
- 2
Lung
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Emerging Molecular Targets in Thymic Epithelial Tumors
FEATURING
Anja Roden
- 8 views
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Current and Future Use of EGFR-Targeted Agents in Lung Cancer
FEATURING
Pilar Garrido
- 2 views
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
Management of Oligoprogressive Disease: Patients With Bone Metastases
FEATURING
Robbe Van den Begin
- 2 views
- September 26, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: RELATIVITY-104 Study - Nivo + Relatlimab With Platinum-Doublet Chemo vs. Nivo + Platinum-Doublet Chemo as 1L Treatment for Stage IV or Recurrent NSCLC
FEATURING
Nicolas Girard
- 31 views
- September 18, 2024